Pancreatic Cancer Research

ResearcherKeio UniversityActive in the last 2 years

Yutaka Nakano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3228-3474; OpenAlex author ID A5075211722, A5122725484. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 7 papers · 2025: 2 papers · 2026: 3 papers

Papers 21

  1. Impact of Sarcopenia During Induction Treatment in Patients With Unresectable Locally Advanced Pancreatic Cancer. Co-author DOI 10.1002/ags3.70078↗
  2. Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02343-2↗
  3. Postoperative risk stratification after upfront surgery for resectable pancreatic ductal adenocarcinoma in the S-1 adjuvant era. Co-author DOI 10.1016/j.pan.2026.05.008↗
  4. Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02): A Phase 2 Clinical Tria… Co-author DOI 10.1245/s10434-025-17661-7↗
  5. Pancreatic Cancer Mimicking Relapse of Autoimmune Pancreatitis: Case Reports. Co-author DOI 10.70352/scrj.cr.25-0076↗
  6. Impact of the COVID-19 pandemic on short-term outcomes after pancreaticoduodenectomy for pancreatic cancer: A retrospective study from the Japanese National Cl… Co-author DOI 10.1002/ags3.12798↗
  7. Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. Co-author DOI 10.1002/cam4.7459↗
  8. Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-024-72569-8↗
  9. Prognosis prediction of PDAC via detection of O-glycan altered extracellular vesicles in perioperative sera. Co-author DOI 10.1111/cas.16341↗
  10. Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study. Co-author DOI 10.1186/s12957-024-03609-w↗
  11. Efficacy and safety of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer Co-author DOI 10.21203/rs.3.rs-4671932/v1↗
  12. Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Co-author DOI 10.3892/ol.2024.14272↗
  13. Long-term survival after surgical resection for bone metastasis from pancreatic cancer: A case report. Co-author DOI 10.1097/md.0000000000035856↗
  14. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  15. Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review. Co-author DOI 10.3748/wjg.v27.i3.294↗
  16. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. Co-author DOI 10.1111/cas.14425↗
  17. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Co-author DOI 10.3390/cancers12092469↗
  18. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline rese… Co-author DOI 10.1186/s12957-019-1687-4↗
  19. Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/mco.2019.1883↗
  20. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. Co-author DOI 10.1038/bjc.2017.479↗
  21. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Co-author DOI 10.1002/cam4.1178↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Kitago · 20 shared papers, 2017–2026 · strength 3.30
  2. Yuta Abe · 19 shared papers, 2017–2026 · strength 3.19
  3. Shutaro Hori · 14 shared papers, 2019–2026 · strength 2.57
  4. Yuko Kitagawa · 15 shared papers, 2017–2026 · strength 2.29
  5. Masayuki Tanaka · 10 shared papers, 2021–2026 · strength 2.05
  6. Yohei Masugi · 11 shared papers, 2019–2026 · strength 1.69
  7. Sho Uemura · 5 shared papers, 2022–2026 · strength 1.06
  8. Yutaka Endo · 7 shared papers, 2018–2025 · strength 0.92
  9. Gaku Shimane · 4 shared papers, 2024–2026 · strength 0.82
  10. Yuko Kitagawa · 4 shared papers, 2024–2025 · strength 0.78
  11. Koichi Aiura · 5 shared papers, 2017–2025 · strength 0.74
  12. Yosuke Uematsu · 2 shared papers, 2025–2026 · strength 0.48
  13. Yutaka Takigawa · 2 shared papers, 2024–2025 · strength 0.40
  14. Junichi Matsui · 2 shared papers, 2024–2025 · strength 0.40
  15. Hiroshi Nishihara · 2 shared papers, 2024 · strength 0.37
  16. Eisuke Iwasaki · 2 shared papers, 2021–2025 · strength 0.34
  17. Hideaki Kojima · 2 shared papers, 2021–2025 · strength 0.34
  18. Satoru Matsuda · 1 shared paper, 2026 · strength 0.30
  19. Kohei Mishima · 1 shared paper, 2026 · strength 0.30
  20. Michiie Sakamoto · 3 shared papers, 2020–2022 · strength 0.29
  21. Yusuke Takemura · 2 shared papers, 2021–2024 · strength 0.29
  22. Yasuaki Kabe · 2 shared papers, 2020–2024 · strength 0.26
  23. Sojun Hoshimoto · 1 shared paper, 2025 · strength 0.22
  24. Masaki Mori · 1 shared paper, 2024 · strength 0.18
  25. Yasuyuki Seto · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.